TSE:IMV

IMV Competitors

C$3.39

+0.05 (+1.50 %)

(As of 04/20/2021 12:00 AM ET)

Add

Compare

Today's Range

C$3.30

Now: C$3.39▼

C$3.42

50-Day Range

C$3.34

MA: C$3.98▼

C$4.84

52-Week Range

C$2.48

Now: C$3.39▼

C$9.25

Volume46,584 shs

Average Volume157,600 shs

Market CapitalizationC$229.54 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

IMV (TSE:IMV) Vs. BU, APS, BLU, TH, NRI, and PLI

Should you be buying IMV stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to IMV, including Burcon NutraScience (BU), Aptose Biosciences (APS), BELLUS Health (BLU), Theratechnologies (TH), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

IMV vs. Burcon NutraScience Stock

IMV (TSE:IMV) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Profitability

This table compares IMV and Burcon NutraScience's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMV	N/A	N/A	N/A
Burcon NutraScience	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for IMV and Burcon NutraScience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMV	0	4	0	0	2.00
Burcon NutraScience	0	0	1	0	3.00

IMV presently has a consensus target price of C$5.08, suggesting a potential upside of 49.95%. Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential downside of 1.19%. Given IMV's higher probable upside, research analysts plainly believe IMV is more favorable than Burcon NutraScience.

Valuation and Earnings

This table compares IMV and Burcon NutraScience's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMV	C$3,000.00	76,513.43	C$-39,136,958.00	C($0.58)	-5.87
Burcon NutraScience	C$12,045.00	44,992.20	C$107,101.00	C$0.00	5,060.00

Burcon NutraScience has higher revenue and earnings than IMV. IMV is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats IMV on 6 of the 8 factors compared between the two stocks.

IMV vs. Aptose Biosciences Stock

IMV (TSE:IMV) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Earnings & Valuation

This table compares IMV and Aptose Biosciences' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMV	C$3,000.00	76,513.43	C$-39,136,958.00	C($0.58)	-5.87
Aptose Biosciences	N/A	N/A	N/A	C($0.84)	-7.20

Aptose Biosciences has lower revenue, but higher earnings than IMV. Aptose Biosciences is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for IMV and Aptose Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMV	0	4	0	0	2.00
Aptose Biosciences	0	0	2	0	3.00

IMV currently has a consensus target price of C$5.08, indicating a potential upside of 49.95%. Aptose Biosciences has a consensus target price of C$12.00, indicating a potential upside of 97.37%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than IMV.

Profitability

This table compares IMV and Aptose Biosciences' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IMV	N/A	N/A	N/A
Aptose Biosciences	N/A	N/A	N/A

IMV vs. BELLUS Health Stock

BELLUS Health (TSE:BLU) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares BELLUS Health and IMV's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BELLUS Health	N/A	N/A	N/A
IMV	N/A	N/A	N/A

Valuation & Earnings

This table compares BELLUS Health and IMV's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BELLUS Health	C$15,000.00	29,298.04	C$-52,720,801.00	C($0.67)	-8.34
IMV	C$3,000.00	76,513.43	C$-39,136,958.00	C($0.58)	-5.87

IMV has lower revenue, but higher earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BELLUS Health and IMV, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BELLUS Health	0	1	2	0	2.67
IMV	0	4	0	0	2.00

IMV has a consensus target price of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher probable upside, analysts clearly believe IMV is more favorable than BELLUS Health.

Summary

IMV beats BELLUS Health on 5 of the 8 factors compared between the two stocks.

IMV vs. Theratechnologies Stock

Theratechnologies (TSE:TH) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for Theratechnologies and IMV, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theratechnologies	0	2	0	0	2.00
IMV	0	4	0	0	2.00

Theratechnologies currently has a consensus price target of C$3.75, indicating a potential downside of 16.67%. IMV has a consensus price target of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher possible upside, analysts plainly believe IMV is more favorable than Theratechnologies.

Valuation and Earnings

This table compares Theratechnologies and IMV's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theratechnologies	C$65.76 million	6.47	C$-35,948,380.00	C($0.38)	-11.84
IMV	C$3,000.00	76,513.43	C$-39,136,958.00	C($0.58)	-5.87

Theratechnologies has higher revenue and earnings than IMV. Theratechnologies is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Theratechnologies and IMV's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theratechnologies	N/A	N/A	N/A
IMV	N/A	N/A	N/A

IMV vs. Nuvo Pharmaceuticals Inc. (NRI.TO) Stock

Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Nuvo Pharmaceuticals Inc. (NRI.TO) and IMV, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvo Pharmaceuticals Inc. (NRI.TO)	0	0	1	0	3.00
IMV	0	4	0	0	2.00

IMV has a consensus target price of C$5.08, indicating a potential upside of 49.95%. Given IMV's higher probable upside, analysts plainly believe IMV is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Profitability

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and IMV's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvo Pharmaceuticals Inc. (NRI.TO)	N/A	N/A	N/A
IMV	N/A	N/A	N/A

Valuation and Earnings

This table compares Nuvo Pharmaceuticals Inc. (NRI.TO) and IMV's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvo Pharmaceuticals Inc. (NRI.TO)	C$76.09 million	5.26	C$-6,980,844.00	C($0.61)	-57.38
IMV	C$3,000.00	76,513.43	C$-39,136,958.00	C($0.58)	-5.87

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than IMV. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

IMV vs. ProMetic Life Sciences Stock

ProMetic Life Sciences (TSE:PLI) and IMV (TSE:IMV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Profitability

This table compares ProMetic Life Sciences and IMV's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	N/A	N/A	N/A
IMV	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for ProMetic Life Sciences and IMV, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMetic Life Sciences	0	0	0	0	N/A
IMV	0	4	0	0	2.00

IMV has a consensus target price of C$5.08, suggesting a potential upside of 49.95%.

Earnings and Valuation

This table compares ProMetic Life Sciences and IMV's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	C$39.91 million	0.00	C$-1,470,117,780.00	C($63.06)	N/A
IMV	C$3,000.00	76,513.43	C$-39,136,958.00	C($0.58)	-5.87

IMV has lower revenue, but higher earnings than ProMetic Life Sciences. IMV is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

IMV Competitors List

Competitor Name	Competitor BTM Rank	Competitor Price	Competitor Price Change	Competitor Market Cap	Competitor Revenue	Competitor P/E Ratio	Competitor Indicator(s)
BU Burcon NutraScience	1.2	$5.06	+0.2%	C$541.93 million	C$12,045.00	5,060.00
APS Aptose Biosciences	1.3	$6.08	+4.8%	C$540.42 million	N/A	-7.20
BLU BELLUS Health	0.5	$5.61	+3.2%	C$439.47 million	C$15,000.00	-8.34
TH Theratechnologies	0.7	$4.50	+0.2%	C$425.70 million	C$65.76 million	-11.84	Gap Up
NRI Nuvo Pharmaceuticals Inc. (NRI.TO)	0.8	$35.18	+0.5%	C$400.57 million	C$76.09 million	-57.38
PLI ProMetic Life Sciences	0.5	N/A	N/A	C$315.66 million	C$39.91 million	-0.22
MDNA Medicenna Therapeutics	0.5	$4.82	+0.6%	C$254.99 million	N/A	-15.60
EMC Emblem	0.5	$1.88	+1.6%	$248.31 million	$5.71 million	-9.89	News Coverage
NEPT Neptune Wellness Solutions	1.2	$1.47	+8.2%	C$243.28 million	C$52.78 million	-1.09	Gap Up
RVX Resverlogix	0.7	$0.89	+2.2%	C$208.25 million	N/A	63.57	Upcoming Earnings News Coverage

FRX Fennec Pharmaceuticals	0.5	$7.85	+2.9%	C$204.12 million	C$170,000.00	-8.21	Gap Up
ONC Oncolytics Biotech	1.2	$3.80	+4.7%	C$200.52 million	N/A	-6.79
ATE Antibe Therapeutics	1.3	$4.27	+6.3%	C$194.32 million	C$9.33 million	-5.43	Gap Down
HBP Helix BioPharma	0.5	$0.88	+3.4%	C$124.20 million	N/A	-16.00
IPA ImmunoPrecise Antibodies	0.4	$11.63	+5.0%	C$123.03 million	C$17.18 million	-54.35
ACST Acasti Pharma	0.8	$0.53	+3.8%	C$88.79 million	C$81,000.00	15.59
NVH Novoheart	0.5	$0.53	+1.9%	C$79.23 million	C$423,500.00	-13.95
PDP Pediapharm	0.5	$0.30	+1.7%	C$66.36 million	C$11.16 million	-4.11
MBX Microbix Biosystems	0.9	$0.60	+1.7%	C$65.67 million	C$11.64 million	-11.76
SBM Sirona Biochem	0.5	$0.36	+4.2%	C$58.80 million	C$123,870.00	-27.69
PMN ProMIS Neurosciences	0.5	$0.18	+0.0%	C$55.07 million	C$1,787.00	-9.00	Gap Down
COV Covalon Technologies	0.6	$1.55	+3.2%	C$37.44 million	C$23.84 million	-6.51
EMH Emerald Health Therapeutics	0.5	$0.25	+2.0%	C$34.02 million	C$13.02 million	-0.36
IGX IntelGenx Technologies	0.9	$0.53	+1.9%	C$30.87 million	C$1.54 million	-6.54
QPT Quest PharmaTech	0.8	$0.11	+4.8%	C$21.76 million	C$38,871.00	0.16	High Trading Volume Gap Up
CZO Ceapro	0.7	$0.72	+2.8%	C$21.65 million	C$16.14 million	21.82
CTX Crescita Therapeutics	0.6	$0.80	+6.3%	C$16.52 million	C$15.64 million	400.00
KNE Kane Biotech	0.4	$0.20	+2.6%	C$14.12 million	C$1.34 million	-5.57	High Trading Volume
GSD Devonian Health Group	0.5	$0.28	+7.1%	C$13.96 million	C$1.59 million	-5.83	Gap Down
PAS Pascal Biosciences	0.6	$0.08	+6.3%	C$12.70 million	N/A	-3.64	Gap Up
NSP Naturally Splendid Enterprises	0.6	$0.06	+0.0%	C$11.06 million	C$2.03 million	-1.40
MPH Medicure	0.7	$1.63	+1.2%	C$10.80 million	C$12.71 million	-1.05	Gap Up
BTI Bioasis Technologies	0.7	$0.33	+3.0%	C$10.16 million	C$4.12 million	30.00	Gap Down
HEM Hemostemix	0.6	$0.34	+1.5%	C$9.07 million	N/A	-2.02	Gap Down
ICO iCo Therapeutics	0.5	$0.11	+0.0%	C$7.69 million	N/A	-8.75
IBT IBEX Technologies	0.7	$0.38	+2.6%	C$6.94 million	C$5.60 million	7.04
IOT Innovotech	0.8	$0.17	+5.9%	C$6.52 million	C$1.04 million	85.00	Gap Down
BCT BriaCell Therapeutics	0.5	$3.69	+3.5%	C$4.48 million	N/A	-1.19
RVV Revive Therapeutics	0.5	$0.08	+12.5%	C$3.62 million	N/A	-3.64	High Trading Volume Gap Down
COT Cotinga Pharmaceuticals Inc. (COT.V)	0.5	$0.04	+71.4%	C$1.54 million	N/A	-0.30	Gap Up
PBS Pacgen Life Science Co. (PBS.V)	0.6	$0.03	+16.7%	C$1.30 million	C$302,079.00	-5.00	Gap Down
MFS Medifocus Inc. (MFS.V)	0.5	$0.01	+0.0%	C$925,000.00	C$2.23 million	-1.00
CHV (CHV)	0.5	N/A	N/A	$0.00	N/A	0.00	High Trading Volume
PREV (PREV)	0.7	N/A	N/A	$0.00	N/A	0.00	High Trading Volume
COM 138267 (COM.TO)	0.5	N/A	N/A	C$0.00	N/A	0.00
MYM 17031	0.4	N/A	N/A	C$0.00	N/A	0.00
CURE Direxion Daily Healthcare Bull 3X Shares	0.5	N/A	N/A	$0.00	N/A	0.00	High Trading Volume Gap Down
HALO Halozyme Therapeutics	1.3	N/A	N/A	C$0.00	C$267.59 million	51.46
LTY Liberty Biopharma	0.6	$2.00	+100.0%	C$0.00	N/A	-12.66	Gap Down
MMJ Matica Enterprises	0.5	N/A	N/A	C$0.00	N/A	0.00	High Trading Volume

This page was last updated on 4/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

IMV Competitors

Adding

Adding

Adding IMV Inc.

Competitors

IMV (TSE:IMV) Vs. BU, APS, BLU, TH, NRI, and PLI

IMV vs. Burcon NutraScience Stock

IMV vs. Aptose Biosciences Stock

IMV vs. BELLUS Health Stock

IMV vs. Theratechnologies Stock

IMV vs. Nuvo Pharmaceuticals Inc. (NRI.TO) Stock

IMV vs. ProMetic Life Sciences Stock

IMV Competitors List

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources